A Phase 1b Study of Lutetium-NeoB Alone and With Radiotherapy and Temozolomide in People With Glioblastoma

Full Title

Phase Ib Dose Finding Study Assessing Safety and Activity of (177Lu)Lu-NeoB in Combination with Radiotherapy and Temozolomide in Subjects with Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma

Purpose

Researchers want to find the highest dose of [177Lu]Lu-NeoB (called Lutetium-NeoB) that can be used safely in people with glioblastoma. Lutetium-NeoB is a form of radioligand therapy (RLT).

RLT is a treatment with a large amount of radioactivity attached to it. RLTs target and destroy cancer cells that make certain proteins. Lutetium-NeoB targets the GRPR protein, which helps glioblastoma cells grow and divide.

If you take part in this study, you will get one of these treatments:

• Lutetium-NeoB with standard temozolomide and external beam radiation therapy if your glioblastoma is newly diagnosed.
• Lutetium-NeoB alone if your glioblastoma has come back after initial external beam radiation therapy and temozolomide.

Who Can Join

To join this study, there are a few conditions. You must:

• Have newly diagnosed or recurrent glioblastoma.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Brandon Imber’s office at 631-212-6346.